156 related articles for article (PubMed ID: 34970085)
21. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
22. A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period.
Blatnik A; Dragoš VŠ; Blatnik O; Stegel V; Klančar G; Novaković S; Drev P; Žagar T; Merlo S; Škof E; Bojadžiski MP; Strojnik K; Krajc M
Arch Pathol Lab Med; 2024 Mar; 148(3):299-309. PubMed ID: 37270804
[TBL] [Abstract][Full Text] [Related]
23. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
Ramos P; Karnezis AN; Craig DW; Sekulic A; Russell ML; Hendricks WP; Corneveaux JJ; Barrett MT; Shumansky K; Yang Y; Shah SP; Prentice LM; Marra MA; Kiefer J; Zismann VL; McEachron TA; Salhia B; Prat J; D'Angelo E; Clarke BA; Pressey JG; Farley JH; Anthony SP; Roden RB; Cunliffe HE; Huntsman DG; Trent JM
Nat Genet; 2014 May; 46(5):427-9. PubMed ID: 24658001
[TBL] [Abstract][Full Text] [Related]
24. Ovarian small cell carcinoma in one of a pair of monozygous twins.
Fahiminiya S; Sabbaghian N; Albrecht S; Nadaf J; Callegaro-Filho D; Foulkes WD
Fam Cancer; 2019 Apr; 18(2):161-163. PubMed ID: 30284660
[TBL] [Abstract][Full Text] [Related]
25. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
[TBL] [Abstract][Full Text] [Related]
26. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
27. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
[TBL] [Abstract][Full Text] [Related]
28. Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix.
Tandon B; Hagemann IS; Maluf HM; Pfeifer JD; Al-Kateb H
Int J Gynecol Pathol; 2017 Nov; 36(6):593-599. PubMed ID: 28177947
[TBL] [Abstract][Full Text] [Related]
29. Multimodal molecular analysis of an atypical small cell carcinoma of the ovary, hypercalcemic type.
David MP; Venkatramani R; Lopez-Terrada DH; Roy A; Patil N; Fisher KE
Cold Spring Harb Mol Case Stud; 2018 Oct; 4(5):. PubMed ID: 30275002
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
Genestie C; Blanc-Durand F; Auguste A; Pautier P; Dunant A; Scoazec JY; Gouy S; Morice P; Bentivegna E; Maulard A; LeFormal A; Devouassoux-Shisheboran M; Leary A
Br J Cancer; 2020 Feb; 122(4):564-568. PubMed ID: 31844183
[TBL] [Abstract][Full Text] [Related]
31. Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
Karnezis AN; Chen SY; Chow C; Yang W; Hendricks WPD; Ramos P; Briones N; Mes-Masson AM; Bosse T; Gilks CB; Trent JM; Weissman B; Huntsman DG; Wang Y
Gynecol Oncol; 2021 Feb; 160(2):568-578. PubMed ID: 33328126
[TBL] [Abstract][Full Text] [Related]
32. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
[TBL] [Abstract][Full Text] [Related]
33. Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review.
Duan H; Gao W; Wang L; Cao F; Teng L
Diagn Pathol; 2021 Apr; 16(1):30. PubMed ID: 33836796
[TBL] [Abstract][Full Text] [Related]
34. Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).
Lang JD; Hendricks WPD
Methods Mol Biol; 2018; 1706():367-379. PubMed ID: 29423809
[TBL] [Abstract][Full Text] [Related]
35. No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour.
Foulkes WD; Clarke BA; Hasselblatt M; Majewski J; Albrecht S; McCluggage WG
J Pathol; 2014 Jul; 233(3):209-14. PubMed ID: 24752781
[TBL] [Abstract][Full Text] [Related]
36. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
Witkowski L; Carrot-Zhang J; Albrecht S; Fahiminiya S; Hamel N; Tomiak E; Grynspan D; Saloustros E; Nadaf J; Rivera B; Gilpin C; Castellsagué E; Silva-Smith R; Plourde F; Wu M; Saskin A; Arseneault M; Karabakhtsian RG; Reilly EA; Ueland FR; Margiolaki A; Pavlakis K; Castellino SM; Lamovec J; Mackay HJ; Roth LM; Ulbright TM; Bender TA; Georgoulias V; Longy M; Berchuck A; Tischkowitz M; Nagel I; Siebert R; Stewart CJ; Arseneau J; McCluggage WG; Clarke BA; Riazalhosseini Y; Hasselblatt M; Majewski J; Foulkes WD
Nat Genet; 2014 May; 46(5):438-43. PubMed ID: 24658002
[TBL] [Abstract][Full Text] [Related]
37. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
[TBL] [Abstract][Full Text] [Related]
38. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA
Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004
[TBL] [Abstract][Full Text] [Related]
39. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
40. [SCCOHT/ovarian rhabdoid tumor: A case report].
Bourgoin R; Cornelis F; Masliah-Planchon J; Genestie C; Laé M
Ann Pathol; 2019 Sep; 39(5):357-363. PubMed ID: 30928254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
